Merck & Co., Inc. Restricted Cash, Current
Merck & Co., Inc. (MRK) had Restricted Cash, Current of $44.00 million as of 2023-06-30, per its 10-Q filed 2023-08-07.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2023-08-07
- 2023-06-30: Restricted Cash, Current $44.00M.
- 2023-03-31: Restricted Cash, Current $31.00M.
- 2022-12-31: Restricted Cash, Current $67.00M.
- 2022-09-30: Restricted Cash, Current $55.00M.
| Period end | Restricted Cash, Current |
|---|---|
| 2023-06-30 | $44.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $31.00M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $67.00M 10-Q · filed 2023-08-07 |
| 2022-09-30 | $55.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $28.00M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $31.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $62.00M 10-K · filed 2023-02-24 |
| 2020-12-31 | $102.00M 10-K · filed 2022-02-25 |
| 2019-12-31 | $256.00M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |